By Bret Jensen:Teva Pharmaceuticals (TEVA) has not been the best performer in my portfolio since I added a position in the stock during the third quarter of 2011. However, since TEVA went under $37 a share in late November, it has been on a solid roll. That momentum is accelerating over the last month and I believe TEVA has a lot more to offer on the upside for the rest of 2012. Momentum drivers for TEVA:
- The company just brought in a highly thought of CEO from Bristol Myers Squibb
- Teva's management announced a $3B stock buyback in late December. This is about 8% of float at current prices.
- The company is going to have a substantial win from Generic Lipitor starting in May.
Key value observations on TEVA:
- Generics are a primary beneficiary of long term demographic trend of aging populations in the developed world as well as the increasing desire
